32024-14-9

Upstream product

• 123-08-0 4-hydroxy-benzaldehyde 
• 1948-40-9 4-hydroxy-3,5-diiodobenzaldehyde 
• 74-88-4 methyl iodide 
• 725252-79-9 3,5-diiodo-4-methoxy-benzaldehyde dimethylacetal 

Downstream Products

• 841233-99-6 (2E)-3-(3,5-diiodo-4-methoxyphenyl)-1-(pyridin-2-yl)prop-2-en-1-one 
• 1351593-60-6 4-(3,5-diiodo-4-methoxybenzyl)-7-ethoxyisoquinolin-8-ol 
• 1345017-07-3 1-methyl-4-(3-fluoro-4-methoxyphenyl)-5-(3,5-diiodo-4-methoxyphenyl)imidazole 
• 1345017-13-1 1-methyl-4-(3-fluoro-4-methoxyphenyl)-5-(3,5-diiodo-4-methoxyphenyl)imidazole hydrochloride 
• 861995-39-3 3,5-diiodo-4,4'-dimethoxy-3'-O-tert-butyldiphenylsilyl-E-stilbene 
• 52273-43-5 4-chloromethyl-2,6-diiodo-anisole 
• 841234-02-4 N,N'-didodecyl-4,4'-{[2-methoxy-5-(2,2':6',2''-terpyridin-4'-yl)benzene-1,3-diyl]bis(ethyne-2,1-diyl)}dibenzamide 
• 841233-97-4 4'-(3,5-diiodo-4-methoxyphenyl)[2,2':6',2'']terpyridine 
• 52273-41-3 3,5-diiodo-4-methoxy-benzyl alcohol 
• 4253-11-6 3,5-Diiodo-4-methoxybenzoic acid 

Relevant academic research and scientific papers

Supramolecular Coordination Polymer Formed from Artificial Light-Harvesting Dendrimer

We report the formation of supramolecular coordination polymers formed from multiporphyrin dendrimers (PZnPM; M = FB or Cu), composed of the focal freebase porphyrin (PFB) or cupper porphyrin (PCu) with eight zinc porphyrin (PZn) wings, and multipyridyl porphyrins (PyPM; M = FB or Cu), PFB or PCu with eight pyridyl groups, through multiple axial coordination interactions of pyridyl groups to PZns. UV-vis absorption spectra were recorded upon titration of PyPFB to PZnPFB. Differential spectra, obtained by subtracting the absorption of PZnPFB without guest addition as well as the absorption of PyPFB, exhibited clear isosbestic points with saturation binding at 1 equiv addition of PyPFB to PZnPFB. Job's plot analysis also indicated 1:1 stoichiometry for the saturation binding. The apparent association constant between PZnPFB and PyPFB (2.91 × 106 M-1), estimated by isothermal titration calorimetry, was high enough for fibrous assemblies to form at micromolar concentrations. The formation of a fibrous assembly from PZnPFB and PyPFB was visualized by atomic force microscopy and transmission electron microscopy (TEM). When a 1:1 mixture solution of PZnPFB and PyPFB (20 M) in toluene was cast onto mica, fibrous assemblies with regular height (ca. 2 nm) were observed. TEM images obtained from 1:1 mixture solution of PZnPFB and PyPFB (0.1 wt %) in toluene clearly showed the formation of nanofibers with a regular diameter of ca. 6 nm. Fluorescence emission measurement of PZnPM indicated efficient intramolecular energy transfer from PZn to the focal PFB or PCu. By the formation of supramolecular coordination polymers, the intramolecular energy transfer changed to intermolecular energy transfer from PZnPM to PyPM. When the nonfluorescent PyPCu was titrated to fluorescent PZnPFB, fluorescence emission from the focal PFB was gradually decreased. By the titration of fluorescent PyPFB to nonfluorescent PZnPCu, fluorescence emission from PFB in PyPFB was gradually increased due to the efficient energy transfer from PZn wings in PZnPCu to PyPFB.

Antineoplastic agents. 548. Synthesis of iodo- and diiodocombstatin phosphate prodrugs

Toward the objective of designing a structurally modified analogue of the combretastatin A-4 phosphate prodrug (1b) with the potential for increased specificity toward thyroid carcinoma, synthesis of a series of iodocombstatin phosphate (11a-h) and diiodocombstatin phosphate prodrugs (12a-h) has been accomplished. The diiodo series was obtained via 8a and 9c from condensation of 4 and 6, and the iodo sequence involved a parallel pathway. Both series of iodocombstatins were found to display significant to powerful inhibition of the growth of a panel of human cancer cell lines and of the murine P388 lymphocytic leukemia cell line. Of the diiodo series, 12a was also found to markedly inhibit growth of pediatric neuroblastoma, and monoiodocombstatin 9a strongly inhibited HUVEC growth. Overall, the strongest activity was found against the breast, CNS, leukemia, lung, and prostate cancer cell lines and the least activity against the pancreas and colon lines. Parallel biological investigations of tubulin interaction, antiangiogenesis, and antimicrobial effects were also conducted.

SUBSTITUTED ISOQUINOLINES AND THEIR USE AS TUBULIN POLYMERIZATION INHIBITORS

The present invention relates generally to substituted isoquinolines and their use as tubulin polymerization inhibitors. In particular, the invention relates to substituted isoquinolines which possess useful therapeutic activity, use of these compounds in methods of therapy and the manufacture of medicaments as well as compositions containing these compounds